Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers.
暂无分享,去创建一个
[1] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[2] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[3] K. Blennow,et al. Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients , 2003, Experimental Neurology.
[4] J. Koenigsknecht-Talboo,et al. Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.
[5] L. Provinciali,et al. Platelet Amyloid Precursor Protein Isoform Expression in Alzheimer's Disease: Evidence for Peripheral Marker , 2011, International journal of immunopathology and pharmacology.
[6] A. Simon,et al. Characterization of plasma β‐secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease , 2012, Journal of neuroscience research.
[7] P. Lewczuk,et al. The sortilin‐related receptor SORL1 and the amyloid cascade: a possible explanation for the concurrent elevation of CSF soluble APPα and APPβ in Alzheimer's disease , 2010, International journal of geriatric psychiatry.
[8] K. Malpass. Alzheimer disease: A novel biomarker to detect early-stage Alzheimer disease , 2011, Nature Reviews Neurology.
[9] A. Kurz,et al. Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[10] J. Stockley,et al. Understanding BACE1: essential protease for amyloid-β production in Alzheimer’s disease , 2008, Cellular and Molecular Life Sciences.
[11] F. Bouwman,et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. , 2006, Clinical chemistry.
[12] A. Drzezga,et al. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. , 2013, Journal of Alzheimer's disease : JAD.
[13] Y. Qian,et al. Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[14] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[15] A. Kurz,et al. Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease , 2013, Translational Psychiatry.
[16] E. Siemers. How can we recognize “disease modification” effects? , 2009, The journal of nutrition, health & aging.
[17] B. Allinquant,et al. Functions of Aβ, sAPPα and sAPPβ : similarities and differences , 2012, Journal of neurochemistry.
[18] J. Witton,et al. The functional neurophysiology of the amyloid precursor protein (APP) processing pathway , 2010, Neuropharmacology.
[19] F. Jessen,et al. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[20] A. Simon,et al. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. , 2008, Clinical biochemistry.
[21] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[22] Y. Stern. Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.
[23] K. Blennow,et al. Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease , 2012, NeuroMolecular Medicine.
[24] Nick C. Fox,et al. Biomarkers for Alzheimer's disease therapeutic trials , 2011, Progress in Neurobiology.
[25] A. Kurz,et al. Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study , 2012, European Psychiatry.
[26] V. Lee,et al. Effects of TNFα-Converting Enzyme Inhibition on Amyloid β Production and APP Processing In Vitro and In Vivo , 2008, The Journal of Neuroscience.
[27] J. O'Brien,et al. PET imaging of brain amyloid in dementia: a review , 2011, International journal of geriatric psychiatry.
[28] C. Brayne,et al. Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. , 2011, Journal of Alzheimer's disease : JAD.
[29] P. Gil,et al. Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI) , 2013, Neurochemical Research.
[30] R. Vassar. BACE1: the beta-secretase enzyme in Alzheimer's disease. , 2004, Journal of molecular neuroscience : MN.
[31] H. Hampel,et al. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[32] A. Kurz,et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid , 2012, Alzheimer's & Dementia.
[33] Dennis W. Dickson,et al. Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.
[34] M. Staufenbiel,et al. Amyloid‐β protein (Aβ) Glu11 is the major β‐secretase site of β‐site amyloid‐β precursor protein‐cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis , 2013, The European journal of neuroscience.
[35] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[36] Dong Han,et al. Diagnostic accuracy of 18F‐FDG and 11C‐PIB‐PET for prediction of short‐term conversion to Alzheimer’s disease in subjects with mild cognitive impairment , 2012, International journal of clinical practice.
[37] Hans Förstl,et al. Kognitive Reservekapazität und ihre Bedeutung für Auftreten und Verlauf der Demenz , 2010, Der Nervenarzt.
[38] A. Kurz,et al. β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau , 2013, Alzheimer's & Dementia.
[39] G. Mead,et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia , 2013, Alzheimer's & Dementia.
[40] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.
[41] W. M. van der Flier,et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. , 2010, Journal of Alzheimer's disease : JAD.
[42] Leslie M. Shaw,et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.
[43] K. Blennow,et al. O3-02-06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease , 2008, Alzheimer's & Dementia.
[44] S. Todd,et al. Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease , 2005 .
[45] Florian Auer,et al. White matter hyperintensities predict amyloid increase in Alzheimer's disease , 2012, Neurobiology of Aging.
[46] M. Wolfe,et al. Tumor Necrosis Factor-α, Interleukin-1β, and Interferon-γ Stimulate γ-Secretase-mediated Cleavage of Amyloid Precursor Protein through a JNK-dependent MAPK Pathway* , 2004, Journal of Biological Chemistry.
[47] P. Sachdev,et al. American Journal of Epidemiology Original Contribution Cognitive Lifestyle and Long-term Risk of Dementia and Survival after Diagnosis in a Multicenter Population-based Cohort , 2022 .
[48] K. Blennow,et al. P3-069: Increased CSF-BACE1 activity is associated with APOE-ϵ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease , 2008, Alzheimer's & Dementia.
[49] D. Craig,et al. Elevated Platelet β-Secretase Activity in Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.
[50] K. Blennow,et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease , 2011, Molecular Neurodegeneration.
[51] L. Grinberg,et al. Neuropathologic features associated with Alzheimer disease diagnosis , 2011, Neurology.
[52] F. Jessen,et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study , 2010, Molecular Psychiatry.
[53] G. Schellenberg,et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease , 2011, Neurobiology of Aging.
[54] K. Blennow,et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[55] N. Bark,et al. Platelet alpha- and beta- secretase activities are not significantly affected by dementia or mild cognitive impairment in Swedish patients. , 2010, Current Alzheimer research.
[56] G. McKhann. Changing concepts of Alzheimer disease. , 2011, JAMA.
[57] R. Shin,et al. Novel α-secretase cleavage of Alzheimer's amyloid β precursor protein in the endoplasmic reticulum of COS7 cells , 2005, Neuroscience Letters.
[58] J. Ringman,et al. Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer's Disease Mutation Carriers , 2012, Dementia and Geriatric Cognitive Disorders Extra.
[59] P. Falkai,et al. New lexicon and criteria for the diagnosis of Alzheimer's disease , 2011, The Lancet Neurology.
[60] Anand Viswanathan,et al. Cerebral amyloid angiopathy in the elderly , 2011, Annals of neurology.
[61] R. Doms,et al. Protein Kinase C-dependent α-Secretase Competes with β-Secretase for Cleavage of Amyloid-β Precursor Protein in the Trans-Golgi Network* , 2000, The Journal of Biological Chemistry.
[62] D. Craig,et al. Platelet β-secretase activity is increased in Alzheimer's disease , 2008, Neurobiology of Aging.
[63] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[64] Hans Förstl,et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease , 2011, Neurology.
[65] Anne Corbett,et al. Alzheimer's disease , 2011, The Lancet.
[66] K. Blennow,et al. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease , 2013, Brain Research.
[67] K. Blennow,et al. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.
[68] O. Hurko,et al. The Uses of Biomarkers in Drug Development , 2009, Annals of the New York Academy of Sciences.
[69] O. Lopez. Mild Cognitive Impairment , 2013, Continuum.
[70] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[71] A. Simon,et al. In Vivo β-Secretase 1 Inhibition Leads to Brain Aβ Lowering and Increased α-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[72] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[73] S. Sparber,et al. Dopamine concentrations in the brainstem-mesencephalon of active rats as compared with passive rats. , 1970, Neuropharmacology.
[74] M. Mattson,et al. An Overview of APP Processing Enzymes and Products , 2010, NeuroMolecular Medicine.
[75] W. Kukull,et al. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.
[76] C. Jack,et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.
[77] G. Weskamp,et al. Mice Lacking the Metalloprotease-Disintegrin MDC9 (ADAM9) Have No Evident Major Abnormalities during Development or Adult Life , 2002, Molecular and Cellular Biology.
[78] A. Drzezga,et al. Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.
[79] Karl Herholz,et al. Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.
[80] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[81] B. Hyman,et al. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.
[82] O. Lopez,et al. Biomarkers in Alzheimer’s Disease , 2011, Front. Neur..
[83] J. Mortimer. The Nun Study: risk factors for pathology and clinical-pathologic correlations. , 2012, Current Alzheimer research.
[84] Jeffrey L. Cummings,et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[85] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[86] N. Bohnen,et al. Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.
[87] E. Godaux,et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.
[88] W. M. van der Flier,et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.
[89] K. Blennow,et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. , 2008, Brain : a journal of neurology.
[90] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[91] Giovanni B. Frisoni,et al. Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .
[92] D. Selkoe. The molecular pathology of Alzheimer's disease , 1991, Neuron.
[93] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[94] E. Kremmer,et al. ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons , 2010, The EMBO journal.
[95] T. Kusaka,et al. Transporters in the brain endothelial barrier. , 2010, Current medicinal chemistry.
[96] Stefan J. Teipel,et al. Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment , 2007 .
[97] E. Peskind,et al. S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10 , 2009, PloS one.
[98] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[99] A. Simon,et al. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex , 2011, Journal of neuroscience research.
[100] K. Blennow,et al. BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease , 2010, Molecular Neurodegeneration.
[101] Asher Mullard. Sting of Alzheimer's failures offset by upcoming prevention trials , 2012, Nature Reviews Drug Discovery.
[102] Nick C Fox,et al. Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[103] Sean D Sullivan,et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[104] Junxia Xie,et al. Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. , 2013, Current Alzheimer research.
[105] K. Blennow,et al. Fluid biomarkers in Alzheimer’s disease – current concepts , 2013, Molecular Neurodegeneration.
[106] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[107] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[108] L. Ferrucci,et al. Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques , 2012, Acta Neuropathologica.
[109] E. Kojro,et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.